Figure 4 shows that treatment of the TAP sufficient RMA cells with Clec9a antibody targeted TAP siRNA inhibited tumor growth provided mice were also treated with Nucl-TAP siRNA. This evidence concerns the gene CLEC9A and neoplasm.